All News

PMR,flag

Secukinumab in Polymyalgia Rheumatica

Jack Cush, MD

Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.

Read Article
PSA%20026.jpg

Can Effective Psoriasis Therapy Prevent Psoriatic Arthritis?

Jack Cush, MD

A review article assesses and integrates mechanistic, imaging, and clinical evidence to examine whether effective treatment of psoriasis may modify the future risk of psoriatic arthritis (PsA).

Read Article
EULAR meeting room

Psoriatic Arthritis: EULAR 2026 Recap

Jack Cush, MD

Years of IL-17 vs. IL-23 debate in PsA finally got tested head-to-head: bimekizumab outperformed risankizumab on joint outcomes in the BE BOLD trial, while a GLP-1 combination study suggests weight and metabolic status are active drivers of PsA — not just comorbidities. This recap also digs into early signals that biologic choice may influence whether psoriasis progresses to PsA, and why some well-controlled patients are still in pain.

Read Article
Canada.maple.leaf

ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis

Jack Cush, MD

In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i recommendations.

Read Article
RheumNow Podcast square

Generic Tofacitinib (6.26.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

Read Article
guidelines.recommendations.jpg

2026 Guidelines for the Treatment of Axial Spondyloarthritis

ACR

New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children.

Read Article
Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

Read Article
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
Spyre Therapeutics topline results of its anti-TL1A Ab (SPY072) in RA (n 133) sub-study: Phase 2 SKYWAY 12wk trial showed 2 doses SPY072 were signif better vs PBO for ACR20 (63% & 58% vs 43%), ACR50 (31% &38% vs 19%), DAS28-CRP reductions (-1.5 & -1.9 vs -1.3). TL1A inhib are https://t.co/S6gapB21uq
Dr. John Cush RheumNow ( View Tweet)
Prolonged exposure to targeted Rx in #SpA not assoc w/ increased cancer risk. French claims study 56,591 SpA pts- 1,224 CA (1,029 solid, 116 Heme). TNFi, IL17i, IL12/23i, IL23i, JAKi Exposure >6 vs ≤6 mos assoc w/ lower CA (HR 0.86; 0.75-0.99); signif for Heme (HR 0.65), not https://t.co/rHAa0CkAjT
Dr. John Cush RheumNow ( View Tweet)
Simple infographic on the MOA of deucravacitinib (Sotyktu). https://t.co/fXbxMAzvAE https://t.co/6IvA0Xz3m2

Links:

Dr. John Cush RheumNow ( View Tweet)
MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG
Dr. John Cush RheumNow ( View Tweet)
COLIPSO prospective study of psoriasis or psoriatic arthritis adults starting ts/bDMARDs; MRI done serially. 35 pts f/u for ~29 wks - MASLD. Only Rx w/ IL-17 inhibitors improved liver fat and inflammation in psoriatic disease as well as clinical outcomes. https://t.co/MFjvh5OJg2 https://t.co/k0C7RSvaaR

Links:

Dr. John Cush RheumNow ( View Tweet)
British Dermatology Biologics registry (BADBIR) 18976 #PSO pts had incidence serious infxns (SIE) 28 SEI/1000 Pt-Yrs; higher if they had prior infxn (79/1000 PYs). SIE signif lower w/ RIZankizumab (HR 0.74-.80) vs BROAD, ETN, other standards Rxs. SIE deaths rare (1.81/1000 PYs) https://t.co/GTr3DLCVXs
Dr. John Cush RheumNow ( View Tweet)
British Dermatology Biologics registry (BADBIR) 18976 #PSO pts had incidence serious infxns (SIE) 28 SEI/1000 Pt-Yrs; higher if they had prior infxn (79/1000 PYs). SIE signif lower w/ RIZankizumab (HR 0.74-.80) vs BROAD, ETN, other standards Rxs. SIE deaths rare (1.81/1000 PYs) https://t.co/5HqJ3zpO0g
Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE

Dr. John Cush RheumNow ( View Tweet)

In the psoriasis-to-PsA transition study at EULAR 2026, which ultrasound finding best distinguished progressing from stable subclinical PsA? Test your knowledge in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/kV0zA7qyg7

Links:

Dr. John Cush RheumNow ( View Tweet)
🏠 Take Home Messages from the early #axSpA session 🔺 Earlier diagnosis is possible and better 🔺 Early axSpA is not synonymous to mild 🔺 Longitudinally, early axSpA is heterogeneous 🔺 MRI has transformed the field ❗️Beware of pitfalls #EULAR2026 @RheumNow https://t.co/IhGQSxssyd

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype Results from the Spanish REGISPON-3 POS1352 #EULAR2026 @RheumNow https://t.co/XicguAdXJ1

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU? Yes! POS 1347 Multicenter randomised open-label trial N=56 #EULAR2026 @RheumNow https://t.co/kP7ropPkpC

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×